63 results
424B3
KA
Kineta Inc
13 Nov 23
Prospectus supplement
5:28pm
of our Common Stock, including any voting rights, until the holder exercises the warrant.
Resale Registration Rights
We have filed this registration
8-K
EX-4.2
KA
Kineta Inc
5 Oct 23
Kineta, Inc. Announces $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
4:05pm
to any voting rights, dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except
8-K
EX-4.3
KA
Kineta Inc
5 Oct 23
Kineta, Inc. Announces $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
4:05pm
; No Settlement in Cash. This Warrant does not entitle the Holder to any voting rights, dividends or other rights as a stockholder of the Company prior
8-K
EX-4.1
p80jrf8gz5svwl0xq7uc
5 Oct 23
Kineta, Inc. Announces $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
4:05pm
424B5
sf71d2g
5 Oct 23
Prospectus supplement for primary offering
10:47am
424B3
6qk8 7igt7wwhk5qj
12 Jun 23
Prospectus supplement
5:01pm
8-K
EX-4.1
dpa jy7su9utlyb2wbx
21 Apr 23
Kineta, Inc. Announces $6 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
5:16pm
8-K
EX-4.3
fnwb56y
21 Apr 23
Kineta, Inc. Announces $6 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
5:16pm
8-K
EX-4.2
nphdz78gt0wgj8e6b0
21 Apr 23
Kineta, Inc. Announces $6 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
5:16pm
424B5
brpycdv6w95hibmie86y
21 Apr 23
Prospectus supplement for primary offering
5:14pm
8-K
EX-3.3
1fi7nnj
22 Dec 22
Kineta Completes Reverse Merger with Yumanity Therapeutics
5:02pm
8-K
EX-10.6
6pd3u0cramm1
22 Dec 22
Kineta Completes Reverse Merger with Yumanity Therapeutics
5:02pm